Implants and biodegradable tissue markers

Patent metadata

Field	Value
Publication number	US-10786581-B2
Application number	US-201916296795-A
Country	US
Kind code	B2
Filing date	Mar 8, 2019
Priority date	Dec 15, 2009
Publication date	Sep 29, 2020
Grant date	Sep 29, 2020

Abstract

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

First claim

The invention claimed is:

1. A hydrogel implant, said hydrogel implant formed by a method that comprises combining one or more precursors that undergo a covalent crosslinking reaction to make a covalently-crosslinked biodegradable hydrogel implant that has a covalently attached radiopaque agent that comprises iodine, wherein the one or more precursors comprise a water soluble branched polyethylene glycol (PEG) with at least four arms wherein a portion of the arms comprise the radiopaque agent linked to the arm via a linkage group and wherein the remaining arms comprise an electrophilic functional group linked to the arm by a hydrolytically labile linkage.

2. The hydrogel implant according to claim 1 , wherein between 25% and 90% of the arms comprise the radiopaque agent linked to the arm via the linkage group.

3. The hydrogel implant according to claim 1 , wherein the electrophilic functional group is selected from carbodiimidazole, sulfonyl chloride, chlorocarbonates, n-hydroxysuccinimidyl ester, succinimidyl ester or sulfasuccinimidyl esters.

4. The hydrogel implant according to claim 1 , wherein the one or more precursors further comprise a multifunctional precursor that comprises two or more nucleophilic functional groups.

5. The hydrogel implant according to claim 4 , wherein the nucleophilic functional groups are amine groups.

6. The hydrogel implant according to claim 4 , wherein the multifunctional precursor comprises trilysine.

7. The hydrogel implant according to claim 1 , wherein the branched polyethylene glycol has a molecular weight ranging from 10,000 to 100,000 Daltons.

8. The hydrogel implant according to claim 1 , further comprising a therapeutic agent or a radiation source.

9. The hydrogel implant according to claim 1 , wherein the hydrogel implant produces degradation products that are absorbed into the circulatory system and cleared from the body via renal filtration.

10. The hydrogel implant according to claim 1 , wherein the hydrogel implant is biodegradable at a time between about 30 and about 365 days.

11. A hydrogel implant, said hydrogel implant formed by a method comprising combining first and second precursors that undergo a covalent crosslinking reaction to make a covalently-crosslinked biodegradable hydrogel implant that has a covalently attached radiopaque agent, the first precursor comprising a water soluble branched polyethylene glycol (PEG) having a plurality of arms wherein a portion of the arms comprise the radiopaque agent linked to the arm via a linkage group and wherein the remaining arms comprise an electrophilic functional group linked to the arm by a hydrolytically labile linkage.

12. The hydrogel implant according to claim 11 , wherein between 25% and 90% of the arms comprise the radiopaque agent linked to the arm via the linkage group.

13. The hydrogel implant according to claim 11 , wherein the electrophilic functional group is selected from carbodiimidazole, sulfonyl chloride, chlorocarbonates, n-hydroxysuccinimidyl ester, succinimidyl ester or sulfasuccinimidyl esters.

14. The hydrogel implant according to claim 11 , wherein second precursor comprises a multifunctional precursor that comprises two or more nucleophilic functional groups.

15. The hydrogel implant according to claim 14 , wherein the nucleophilic functional groups are amine groups.

16. A hydrogel implant, said hydrogel implant formed by a method comprising combining first and second precursors that undergo a covalent crosslinking reaction to make a covalently-crosslinked hydrogel implant that has a covalently attached radiopaque agent, the first precursor comprising a branched component having a plurality of arms wherein a portion of the arms comprise the radiopaque agent linked to the arm via a linkage group and wherein the remaining arms comprise an electrophilic functional group linked to the arm by a hydrolytically labile linkage, and the second precursor comprising a multifunctional precursor that comprises two or more nucleophilic functional groups reactive with the electrophilic functional groups.

17. The hydrogel implant according to claim 16 , wherein between 25% and 90% of the arms comprise the radiopaque agent linked to the arm via the linkage group.

18. The hydrogel implant according to claim 16 , wherein the electrophilic functional group is selected from carbodiimidazole, sulfonyl chloride, chlorocarbonates, n-hydroxysuccinimidyl ester, succinimidyl ester or sulfasuccinimidyl esters.

19. The hydrogel implant according to claim 16 , wherein the nucleophilic functional groups are amine groups.

20. The hydrogel implant according to claim 16 , wherein the first precursor is a water soluble branched polymer comprising at least four arms.

Assignees

• Incept Llc

Inventors

• Campbell Patrick
• Sawhney Amarpreet S

Classifications

• A61L27/50 Primary

  Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

• A61L27/58

  Materials at least partially resorbable by the body · CPC title

• A61K51/1244

  microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title

• A61L31/18

  Materials at least partially X-ray or laser opaque · CPC title

• A61L31/145

  Hydrogels or hydrocolloids · CPC title